Zruntz is a THC-dominant dried cannabis flower presented in a 5g unit, manufactured under full GMP conditions by ECS Botanics in Australia. The flower is cultivated by licensed global partners operating under validated quality systems and is processed at ECS’s GMP-certified Australian facility. Pharmaceutical-grade post-harvest procedures are applied, including microbial and stability testing, QA batch release, and packaging in tamper-evident, child-resistant containers.

This chemovar was developed through a genetic cross between The Original Z, a proprietary cultivar from TerpHogz Genetics, and Runtz. It has been stabilised through multiple selection cycles to prioritise consistency in cannabinoid content and terpene expression. The current batch expresses ~22% /w total cannabinoids, predominantly as Δ9-THC.

The terpene profile is batch-specific but commonly includes limonene, beta-caryophyllene, and myrcene. No therapeutic claims are made regarding individual constituents.

Intended exclusively for vaporised administration. Prescribers should assess clinical suitability on a patient-specific basis.

Zruntz is available under the Special Access Scheme Category B or Authorised Prescriber pathways in accordance with TGO 93. Batch-specific Certificates of Analysis confirming cannabinoid concentration, and microbial compliance are available upon request.